Here’s a finding I’ve been watching closely: a new, larger randomized trial suggests prenatal phosphatidylcholine supplements—providing about 9 g phosphatidylcholine daily—may support early brain-related behavior and cognition up to age four. That sounds promising, but the real question is, what does the evidence truly allow us to say?
What the study does, and doesn’t, show
This trial at the University of Colorado enrolled 206 pregnant people starting around 16 weeks gestation. They were randomized to phosphatidylcholine (about 9 g daily) or placebo through delivery. Follow-up assessments from 18 months to 4 years of age focused on parent-rated behavior, social withdrawal, attention, and IQ.
The findings: compared to placebo, children exposed prenatally to phosphatidylcholine showed fewer pervasive withdrawn behaviors and had a higher average IQ (+7.8 points on WPPSI‑IV full-scale IQ) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/42896815/?utm_source=openai)).
Exploratory analyses suggested fewer children scored in the autism-referral range (1 versus 10 out of 71) and more had high IQ (>120) after phosphatidylcholine exposure ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/42896815/?utm_source=openai)).
At first glance, these results hint at meaningful effects. The study even reports no safety concerns for mothers or children ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/42896815/?utm_source=openai)).
Where uncertainty remains
First, parents rated behavior, which can introduce perception bias—even without knowing exposure, our expectations shape judgment. And though the IQ difference was statistically significant, the sample size was moderate and about one-third of participants were lost by the four-year follow-up ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/42896815/?utm_source=openai)).
Second, behavior and IQ in early childhood don’t guarantee lasting neurodevelopmental advantage. Does this translate into school performance, social functioning, or learning years later? We can’t yet tell.
What precedes this new trial?
Previous smaller trials reported that prenatal phosphatidylcholine improved newborn neurophysiology—specifically neural inhibition responses to repeated stimuli—and at 40 months, reduced attention and social withdrawal issues ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/42896815/?utm_source=openai)).
More broadly, observational data shows that higher dietary choline intake in adults (dietary—not supplemental) is associated with lower odds of cognitive decline and dementia, with a sweet spot near 350–400 mg/day ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/42735059/?utm_source=openai)). Still, those are associations, not proof.
Mind the mechanism—but stay grounded
Choline plays many roles—acetylcholine precursor, methyl donor, and part of cell membranes. It’s biologically plausible that maternal intake might support fetal neurodevelopment, particularly through α7-nicotinic receptors important in synapse formation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/42896815/?utm_source=openai)).
Still, plausibility doesn’t replace outcome-based evidence. We’ve seen promising mechanisms that don’t hold up in the real world.
What’s often inferred beyond the evidence
- That more choline is always better. This study used a high dose—9 g of phosphatidylcholine, which roughly equals 900 mg of choline—much more than typical dietary intake, and it hasn’t been tested across populations or doses beyond this scenario.
- That increasing early IQ ensures better life outcomes. Early IQ gains may or may not persist—and are shaped by a web of environmental, educational, and social factors long after birth.
- That choline supplementation in all pregnancies offers benefit. This trial doesn’t speak to people who have adequate choline from diet or who start later in pregnancy.
Before you add it
Any supplement—even phosphatidylcholine—can have effects and may interact with existing conditions or medications. Evidence didn’t raise safety concerns here, but we don’t yet have broad, long-term data on outcomes beyond age four. Supplements aren’t risk‑free just because trials report no immediate issues.
Where this leaves us
Here’s the orientation: prenatal phosphatidylcholine shows promise, particularly in reducing early social withdrawal and boosting early IQ. But the evidence is still early. Key questions remain: Do the benefits persist? Are there unintended effects later? What’s the right dose, timing, and target group?
Rather than treating this as a call to action, I see it as a prompt: How might choline intake shape early brain development—and under what conditions does it matter most? That’s a richer question worth exploring further.